NCT07170319View on ClinicalTrials.gov

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Overweight or Obesity
Interventions
DRUG

IBI3032

IBI3032. Method of administration: oral, fasted administration.

DRUG

placebo

Placebo (without active ingredients). Method of administration: oral, fasted administration.

Trial Locations (1)

230000

The Frist Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

Innovent Biologics Technology Limited (Shanghai R&D Center)

INDUSTRY